Epix, a struggling biotechnology firm working with British drug maker GlaxoSmithKline PLC to develop an Alzheimer's disease drug, says it is winding down its operations and selling off assets to pay off creditors.
Struggling biotech Epix Pharmaceuticals goes bustCourtesy Newsvine - business Mon, 07/20/2009 - 17:39
Epix, a struggling biotechnology firm working with British drug maker GlaxoSmithKline PLC to develop an Alzheimer's disease drug, says it is winding down its operations and selling off assets to pay off creditors. Related itemsGSK receives EU approval for prostate drug
FDA rejects GlaxoSmithKline nausea, vomiting drug
Glaxo signs deal with Concert on early stage drugs
BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
Uniden TRU9496 2-Line Corded/Cordless Digital...
|
Popular by tags WeekMonth |
Post new comment